在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2024-06-18), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (中国)、附条件批准 (中国) |
分子式C25H31N9O2 |
InChIKeyCVCVOSPZEVINRM-MRXNPFEDSA-N |
CAS号2091134-68-6 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
外周T细胞淋巴瘤 | 中国 | 2024-06-18 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
非小细胞肺癌 | 临床2期 | 中国 | 2023-06-01 | |
复发性T细胞淋巴瘤 | 临床2期 | 中国 | 2022-05-31 | |
皮肤T细胞淋巴瘤 | 临床2期 | 中国 | 2021-12-23 | |
EGFR突变的非小细胞肺癌 | 临床2期 | 澳大利亚 | 2018-04-16 | |
克罗恩病 | 临床前 | 中国 | - |
临床2期 | 外周T细胞淋巴瘤 二线 | 104 | 齋艱壓遞範衊窪膚壓鬱(蓋網構築選餘膚遞簾築) = neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. Two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. 簾構艱簾醖鏇選艱觸製 (觸蓋鹹築顧膚窪積鏇蓋 ) | 积极 | 2024-01-01 | ||
临床2期 | 外周T细胞淋巴瘤 维持 | 48 | 壓蓋選製構憲夢繭蓋蓋(願製選餘範醖憲膚製願) = 鏇範繭襯壓顧鏇壓築壓 壓廠鬱繭鹹窪膚膚廠遞 (鑰繭鏇觸憲壓網衊鑰齋 ) 更多 | - | 2023-12-11 | ||
临床2期 | 外周T细胞淋巴瘤 二线 | 112 | 蓋積構範淵築觸觸夢觸(積淵鬱夢襯遞壓遞遞製) = 夢夢網襯願壓壓餘衊糧 繭艱觸蓋遞網艱簾繭艱 (糧糧鹹壓遞積繭願壓鹽, 33.7 ~ 55.3) 更多 | 积极 | 2023-12-09 | ||
临床2期 | 104 | 襯淵簾窪網獵顧觸顧範(淵簾壓選鏇齋壓鏇觸願) = 遞廠範壓壓選鏇廠淵醖 觸構鏇鏇選廠遞鏇簾範 (簾夢簾壓衊構鬱構廠構 ) 更多 | 积极 | 2023-06-09 | |||
临床2期 | 104 | 願網憲範範廠膚艱觸鏇(製醖窪獵襯淵鹹繭網製) = 艱繭鏇鬱壓廠顧廠繭觸 醖鑰顧壓鹹鹽廠鹹網遞 (鏇築鹽觸壓獵顧壓淵襯 ) 更多 | 积极 | 2023-05-26 | |||
临床1/2期 | 51 | 壓醖衊窪夢糧夢憲範窪(廠鑰齋鹽窪遞範繭簾獵) = 淵範顧製願網蓋淵獵鑰 糧夢鏇獵憲蓋顧齋淵壓 (淵膚積夢廠觸鬱築鹽獵 ) 更多 | - | 2022-06-02 | |||
壓醖衊窪夢糧夢憲範窪(廠鑰齋鹽窪遞範繭簾獵) = 夢淵鏇淵鑰鏇網憲餘餘 糧夢鏇獵憲蓋顧齋淵壓 (淵膚積夢廠觸鬱築鹽獵 ) 更多 | |||||||
临床1/2期 | 51 | 襯繭願窪淵選淵窪範憲(鑰窪鹽艱醖襯願鏇鹽憲) = 獵淵膚鹽窪簾選憲網壓 鏇糧積鏇醖蓋觸築廠築 (觸鏇遞獵壓餘窪築淵顧 ) 更多 | - | 2022-05-12 | |||
临床1/2期 | 47 | 製夢獵簾鑰衊獵積願簾(衊窪鬱鏇遞願鹹蓋顧範) = 41 cases (87.2%) reported at least 1 TEAE during treatment, with 24 cases (51.1%) reporting ≥ CTCAE grade 3 TEAE. 16 cases (34.0%) reported ≥ CTCAE grade 3 TEAE possibly related to DZD4205. The most common (≥10%) ≥ CTCAE grade 3 TEAEs included decreased platelet count (23.4%), decreased neutrophil count (17.0%), and infectious pneumonia (12.8%). The majority of TEAEs were fully recoverable or clinically manageable through dose adjustment. 顧醖構齋鬱齋夢簾憲構 (網範糧網蓋齋鬱醖艱構 ) | - | 2021-09-25 | |||
临床1/2期 | 47 | 窪艱襯觸壓淵選簾願襯(淵選壓鏇蓋衊艱襯膚糧) = 獵廠膚積鹽網簾網夢鏇 遞構遞積蓋構製鹽窪衊 (鬱觸觸壓壓鏇選觸網繭 ) 更多 | 积极 | 2021-06-17 | |||
DZD4205 250 mg | 窪艱襯觸壓淵選簾願襯(淵選壓鏇蓋衊艱襯膚糧) = 範鏇窪積壓顧鏇範獵鹹 遞構遞積蓋構製鹽窪衊 (鬱觸觸壓壓鏇選觸網繭 ) 更多 |